Incretin Therapy and Exercise in Type 2 Diabetes
Key facts
- Where
- Regina, CanadaSee the site
Where in Canada
- Centre for KinesiologyRegina, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Regina
- Trial code
- NCT07833813
- Record updated
- 22 September 2026
- Original description
This study will examine changes in brain and physical health in adults with type 2 diabetes who are initiating incretin-mimetic therapy (e.g., Ozempic, Mounjaro), and determine whether adding structured exercise provides additional benefits. Participants will be randomized to receive incretin-mimetic therapy alone or incretin-mimetic therapy plus a structured exercise program for 24 weeks. If the participant is randomly assigned to the incretin-based therapy alone group, they will have the opportunity to complete the same structured exercise program after the 24-week study period is complete.Read full original descriptionShow less
Effects of Incretin Memetics and Exercise on Gut-brain and Metabolic Health in Persons With Type 2 Diabetes
This study will examine changes in brain and physical health in adults with type 2 diabetes who are initiating incretin-mimetic therapy (e.g., Ozempic, Mounjaro), and determine whether adding structured exercise provides additional benefits. Participants will be randomized to receive incretin-mimetic therapy alone or incretin-mimetic therapy plus a structured exercise program for 24 weeks. If the participant is randomly assigned to the incretin-based therapy alone group, they will have the opportunity to complete the same structured exercise program after the 24-week study period is complete.
Brain health will be assessed through cognitive performance, mental health, and brain-mediated appetite regulation. The study will also assess gut microbiota and motor-cortex neuroplasticity as potential factors associated with changes in brain health, as well as glucose regulation, body composition, physical function, and cardiorespiratory fitness. Assessments will be completed at baseline, 8 weeks, and 24 weeks. Findings will help determine how incretin-mimetic therapy and exercise can be integrated to support brain and physical health in adults with type 2 diabetes.
Inclusion: adults aged 18 years or older; diagnosed with pre diabetes or type 2 diabetes; prescribed incretin-based therapy (e.g., semaglutide or tirzepatide); able and willing to participate in the study assessments and, if randomized to the exercise group, the 24-week structured exercise program; able to provide informed consent.
Exclusion: current use of incretin-based therapy outside the study-defined enrollment window; any other medical condition or circumstance that, in the opinion of the research team, would interfere with safe participation or completion of study procedures; pregnant or planning to become pregnant during the study period.